Zentalis Pharmaceuticals, Inc. (ZNTL)
| Market Cap | 291.15M +187.8% |
| Revenue (ttm) | n/a |
| Net Income | -124.13M |
| EPS | -1.74 |
| Shares Out | 71.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,593,579 |
| Open | 4.320 |
| Previous Close | 4.280 |
| Day's Range | 3.915 - 4.390 |
| 52-Week Range | 1.130 - 6.950 |
| Beta | 2.00 |
| Analysts | Buy |
| Price Target | 6.60 (+61.37%) |
| Earnings Date | May 12, 2026 |
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ZNTL stock is "Buy." The 12-month stock price target is $6.6, which is an increase of 61.37% from the latest price.
News
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibi...
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting advancement in registration-intended trials DENALI Phase 2 tri...
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrolling ASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval...
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibi...
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June
Zentalis to present azenosertib preclinical data in TNBC at AACR meeting
Zentalis (ZNTL) announced data from two posters being presented at the 2026 American Association for Cancer Research Annual Meeting, taking place April 17-22, 2026, in San Diego, CA. The data…
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhi...
Zentalis price target raised to $10 from $6 at Guggenheim
Guggenheim raised the firm’s price target on Zentalis (ZNTL) to $10 from $6 and keeps a Buy rating on the shares, citing increased probability of success assumptions in platinum-resistant ovarian…
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups Azenosertib ther...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhi...
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval On track to initiate the ASPENOVA Phas...
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhi...
Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Azenosertib is advancing in platinum-resistant ovarian cancer with ongoing DENALI and ASPENOVA trials, targeting cyclin E1-positive patients and aiming for accelerated and full approval. The MIRROR study will explore earlier-line combinations, while regulatory and operational milestones are on track.
Zentalis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Azenosertib is advancing in late-stage trials for PROC patients with high Cyclin E1 expression, targeting a 21,500-patient market in the US, EU4, and UK. The DENALI and ASPENOVA trials are on track, with consistent efficacy, manageable safety, and regulatory alignment for accelerated approval.
Zentalis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Leadership is advancing azenosertib as a first oral, non-chemo option for PROC, with pivotal DENALI and ASPENOVA trials underway. The drug targets Cyclin E1 positive patients, offering improved quality of life and manageable safety, with regulatory alignment for accelerated and full approval.
Zentalis Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Azenosertib is advancing through pivotal trials for platinum-resistant ovarian cancer with high cyclin E1, using a biomarker-driven approach and adaptive trial designs to accelerate approval. The drug shows a favorable safety profile and differentiation from existing therapies, with future plans for combinations and potential expansion into other indications.
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhib...
Zentalis provides update, key milestones in 2025, expectations for 2026
Zentalis (ZNTL) Pharmaceuticals provided a corporate update and highlighted key milestones and expected momentum in the azenosertib development program for 2026. 2025 Accomplishments: Completed enroll...
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval Initiation of the...
Zentalis Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference
Azenosertib demonstrates strong efficacy and safety in Cyclin E1-positive PROC, with a phase two trial underway and a phase three confirmatory study planned for 2026. The companion diagnostic is ready, and robust site activation supports global enrollment.
Zentalis Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Azenosertib is advancing as a differentiated, oral therapy for platinum-resistant ovarian cancer, with strong response rates and a favorable safety profile. The DENALI trial is on track for top-line data by end of 2026, and combination strategies are being explored for broader impact.
Zentalis price target lowered to $4 from $8 at Morgan Stanley
Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Zentalis (ZNTL) to $4 from $8 and keeps an Equal Weight rating on the shares after the company reported…
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated appro...
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertib Presentations feature data from first-in-human Pha...
Zentalis board member Letai frontrunner to lead NCI, STAT reports
Anthony Letai, a cancer researcher and oncologist at the Dana-Farber Cancer Institute and Harvard University and a member of the scientific advisory board at Zentalis (ZNTL), has emerged as a…